Labiotech.eu

News and Trends 24 May 2015

Pluristem accelerates its Cell Therapy program thanks to the EMA

Pluristem Therapeutics has good reasons to celebrate: its PLX cell program in critical limb ischemia is taking the fast line to the market. The program is the first to have been selected for the European Medicines Agency’s Adaptive Pathways pilot project, which aims at accelerating the access for patients to new medicines. The purpose of Europe’s Adaptive Pathways is […]

May 24, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 May 2015

Genzyme joins the never-ending list of Ablynx’ partners

Genzyme is joining Ablynx’ partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Sanofi subsidiary now wants to try out the Nanobody technology of Ablynx against a target at the origin of multiple sclerosis. Genzyme wants to investigate nanobodies against a target that specifically aligns with Genzyme’s early-stage multiple […]

May 22, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 22 May 2015

arGEN-X’ Antibody Platform struck a new Dermatology alliance

arGEN-X and LEO Pharma allied to develop innovative antibody-based solutions for the treatment of chronic inflammation underlying many skin conditions. The deal amounts to a total of €104.5M, from which arGEN-X will receive €4.5M as an upfront payment and up to €100M in royalties. LEO Pharma will receive exclusive access to an already existing arGEN-X antibody […]

May 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 May 2015

Fluorescent antibodies to guide Cancer surgery

French oncologist SurgiMab has started a first-in-human phase I study for its molecule SGM-101 launched at the Montpellier Cancer Institute. SurgiMab is developing antibody-fluorochrome conjugates to be used as in vivo diagnostic agents in oncology. SGM-101 is a fluorescent conjugate that consists on a tumor-specific monoclonal antibody and a near-infrared emitting fluorochrome. Thanks to this conjugate, oncology surgeons will […]

May 22, 2015 - 1 minutemin - By Lourdes Riquelme

IBN One Cristal union Global bioenergies

News and Trends 21 May 2015

Will France become a leader in isobutene production?

Cristal Union and Global Bioenergies have formed a joint venture, entitles IBN-One, to build and operate France’s first bio-sourced isobutene production plant. IBN-One is a limited liability corporation jointly owned by the two companies. The two French companies already collaborated to develop the scaling up of the isobutene production process. Thanks to the partnership, the […]

May 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 May 2015

The most effective Test for Ovarian Cancer raised €7.4M

Cancer is a devastating disease and, despite all the best efforts to develop new personalized medicines, too many lives end every year because of it. However, this trend might be about to change, after the latest study from University College London, published in the Journal of Clinical Oncology last week. The study highlighted that ROCA, […]

May 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 May 2015

[UPDATE] Galapagos with €277.3M, made the Biggest European Biotech IPO ever on NASDAQ

[UPDATE 20/05/2015]: Galapagos announced the closing of its NASDAQ IPO, where the company raised a total of €277.3M. Galapagos has once again made the front page thanks to its unbeaten IPO. The company just raised €240M on Nasdaq, becoming the biggest European biotech IPO ever on the US stock market. The Belgium company just ranked […]

May 20, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 May 2015

Danish Startup Biosyntia grabs €1.7M to Inject Synthetic Biology into Vitamin Production

Biosyntia is a Danish start-up company in the synthetic biology field. The company aims at replacing chemical-based vitamin production by sustainable and fermentation-based processes. Yesterday, during our Denmark Biotech Tour, we met Andreas Laustsen, one of Biosyntia‘ founders who told us that the company has just raised €1,7M from Novo Seeds. The startup was founded in 2012 by […]

May 20, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 20 May 2015

Ipsen acquired OctreoPharm to strengthen its Oncology presence

Ipsen is determined to increase its presence in the oncology field, by acquiring OctreoPharm Sciences. The German life sciences company is focused on the development of radioactive labeled compounds for molecular imaging diagnostics and therapeutic applications. OctreoPharm’s shareholders are eligible to receive up to a total of approximately €50M for the purchase of 100% of […]

May 20, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 May 2015

PsiOxus raised €34.7 Million from First-Class investors

PsiOxus Therapeutics has closed a Series C financing round of €34.7M (£25 million) to progress its lead clinical candidate, enadenotucirev, and a pipeline of follow-on oncolytic programmes. Neil Woodford’s fund, GlaxoSmithKline’s VC unit and Imperial Innovations from Imperial College of London, amongst others, are behind the financing. PsiOxus’ lead product, enadenotucirev, is an oncolytic virus that, […]

May 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 May 2015

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next major blockbusters. This new and latest acquisition by Boehringer, is yet another sign of the growing interest for NASH treatments, already chased by companies such as Intercept, Genfit or Gilead. NASH, or non-alcoholic steatohepatitis, is regarded as […]

May 19, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 18 May 2015

Baxter’s spinoff Baxalta is building up its Oncology portfolio

Baxter has purchased Sigma-Tau’s portfolio of cancer treatments for €793.5M ($900 million). With this important acquisition, Baxter is reinforcing its oncology presence by owning Oncaspar, a treatment against acute lymphocytic leukemia. Oncaspar is the only FDA-approved pegylated formulation of L-asparaginase, the enzyme that depletes the aminoacid asparagine. Whilst normal cells can produce asparagine, leukemic cells […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Pluristem accelerates its Cell Therapy program thanks to the EMA

Genzyme joins the never-ending list of Ablynx’ partners

arGEN-X’ Antibody Platform struck a new Dermatology alliance

Fluorescent antibodies to guide Cancer surgery

Will France become a leader in isobutene production?

The most effective Test for Ovarian Cancer raised €7.4M

[UPDATE] Galapagos with €277.3M, made the Biggest European Biotech IPO ever on NASDAQ

Danish Startup Biosyntia grabs €1.7M to Inject Synthetic Biology into Vitamin Production

Ipsen acquired OctreoPharm to strengthen its Oncology presence

PsiOxus raised €34.7 Million from First-Class investors

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Baxter’s spinoff Baxalta is building up its Oncology portfolio

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!